PPT-NCI P01: Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing

UW TRT P01 Overview The First TRT PO1 Awarded Jamey Weichert PhD Prof of Radiology Medical Physics and Pharmaceutics To develop a broad mechanistic understanding of the immunomodulatory capacity of TRT and to evaluate TRT as . chemotherapy, targeted molecular therapies and other promising modalities, the Proton Therapy Center is leading the next generation of lung cancer care, research, education and prevention. Jame Unimolecular. Micelles for Targeted Cancer Therapy. Shaoqin “Sarah” Gong, University of . Wisconsin-Madison, DMR 032187. Tumor-targeting multifunctional . unimolecular. micelles that exhibit a pH-triggered drug release profile and excellent . Ben Ho Park MD PhD. Johns Hopkins University. Financial Disclosures. I have financial relationships with commercial entities that are relevant to the content of this presentation.. Royalties from Horizon Discovery, LTD. Program Goals. Program Outline. History of Carcinoid Tumors. Features of NETs. Incidence of NETs Over Time by Primary Site. Are NETs Really That "Rare"?. Patient Characteristics That Affect Treatment Selection. Molecular Pathology Director: Frederick Nolte, Ph.D.. Cytogenetics and Molecular Genetics Director: . Daynna. Wolff, Ph.D.. Medical Director: Cynthia Schandl, M.D., Ph.D.. Associate Director: Julie Woolworth Hirschhorn, Ph.D.. Jeffrey Ware, MD, Ronald Wolf, MD, PhD, Harish . Poptani. , PhD, Donald O’Rourke, MD, Suyash Mohan, MD. Neuroradiology Division. Department of Radiology . University of Pennsylvania. ASNR 2015 Annual Meeting . Gaddikeri. 1. , . Kedar. Sharbidre. 1. , . Miral. Jhaveri. 1. and Ashok Srinivasan. 2. Rush University Medical Center, Chicago, IL. 1. and University of Michigan, Ann Arbor, MI. 2. Control no. 1232. Roger J. Packer, MD. Senior Vice-President Neuroscience and Behavioral Medicine. Director, Brain Tumor Institute. Children’s National Health System. Washington, DC. Welcome to CBTTC. CNHS honored to be a member. in vivo. stability of novel . radiometal. -chelate conjugates for applications in nuclear . medicine. Monika . Stachura. on behalf of the P501 collaboration. IS501 Collaboration. 2. Valery . Radchenko. for Cancer and TRIUMF’s Role . Joseph G. Jurcic, MD. Professor of Medicine at CUIMC. Director, Hematologic Malignancies. Columbia University Irving Medical Center. Attending Physician, New York-Presbyterian Hospital. August 23. rd. , 2022. LA-UR-18-28992. T.E. Mastren and . M.E. Fassbender. Los Alamos National Laboratory, P.O. Box 1663, Los Alamos, NM 87545, USA. 18. th. Workshop on . Targetry. and Target Chemistry (WTTC 18). August 25, 2022. Aivija Grundmane, . TRIUMF/Simon Fraser University. Carbo-. Bague. . et al. , . Encyclopedia. of Inorganic and Bioinorganic Chemistry. , 2021.. Meitner-Auger Emitters. . for Targeted Radionuclide Therapy. Infusion Therapies. Aditya Bardia MD, MPH . Massachusetts General Hospital, . Dana Farber/Harvard Cancer Center,. Harvard Medical School, Boston, MA. .. . No Disclosure. No Relevant Disclosures. . To understand the principle of targeted therapies and importance of routine tumor genotyping in cancer . How they work and the future of medicine. Every cell has a set lifespan. After that lifespan has been reached, a cell undergoes apoptosis (programmed cell death). The life(span) of a cell. How does apoptosis work?.